Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged 15 to 49 years~* Attending ANC clinic for the first time in this pregnancy~* Assigned routine ANC at a HCC health clinic~* Has experienced quickening (feeling the movements of the fetus)~* Gestation of 16 weeks to 32 weeks (as assessed by the last menstrual period \[LMP\] or by palpation if LMP is not available)~* Willing to adhere to all requirements of study~* Willing to provide informed written consent~* Planning to stay in Honiara for antenatal care and delivery~Exclusion Criteria:~* Used chloroquine prophylaxis in the current pregnancy before this ANC visit~* A history of allergic reaction to sulfa drugs (SP or cotrimoxazole~* Haemoglobin of \< 7 g/dl~* Using folic acid in a dose of 5 mg daily (a dose of 1 mg daily or less is acceptable)~* Not willing to adhere to study requirements~* Women who are severely ill

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Chloroquine prophylaxis (Type: ACTIVE_COMPARATOR): 300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
- IPTp with Sulphadoxine-pyrimethamine (Type: ACTIVE_COMPARATOR): 3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).